Lenalidomide or Observation in Treating Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase III, Phase IIBiomarker/Laboratory analysis, Treatment18 and overE3A06
NCI-2011-02057, CDR0000682012, ECOG-E3A06, NCT01169337

Trial Description

Summary

This randomized phase II/III trial studies how well lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk asymptomatic (smoldering) multiple myeloma. Biological therapies such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether lenalidomide is effective in treating patients with high-risk smoldering multiple myeloma than observation alone.

Further Study Information

PRIMARY OBJECTIVES:

I. To study the risk of grade 3 adverse events that affect vital organ function (such as cardiac, hepatic or thromboembolic) or any grade 4 or higher non-hematologic adverse events among patients receiving lenalidomide as treatment for high-risk asymptomatic, smoldering multiple myeloma. (Phase II)

II. To compare progression free survival where failure is defined as death or the development of symptomatic myeloma indicating treatment between patients receiving lenalidomide versus observation alone in high-risk asymptomatic, smoldering multiple myeloma. (Phase III)

SECONDARY OBJECTIVES:

I. To assess the response to therapy of patients treated with lenalidomide as treatment for asymptomatic, smoldering multiple myeloma. (Phase II)

II. To determine and compare the response rate, time to progression, 1-year progression-free survival probability, and overall survival between patients randomized to receive lenalidomide or observation in the setting of asymptomatic myeloma. (Phase III)

III. To estimate the incidence of adverse events in patients receiving lenalidomide therapy for early-stage multiple myeloma. (Phase III)

TERTIARY OBJECTIVES:

I. To describe the cohort in terms of gene expression profiling (GEP) and cytogenetic risk classification and evaluate baseline immune and magnetic resonance imaging (MRI) parameters. (Phase II)

II. To evaluate the impact of therapy within GEP-defined risk groups and GEP as a prognostic marker. (Phase III)

III. To study the effects of lenalidomide on laboratory markers of immune function. (Phase III)

IV. To study the prognostic value of MRI-detected asymptomatic bone disease on clinical outcome. (Phase III

V. To evaluate the prognostic effect of baseline high-risk cytogenetic abnormalities on clinical outcome. (Phase III)

QUATERNARY OBJECTIVES:

I. To compare quality of life (QOL) change between treatment and observation arms based on the functional (FWB) and physical (PWB) well-being components of the Functional Assessment of Cancer Therapy (FACT)-General (G) patient-reported outcome (PRO) measure from registration (prior to initiation of treatment) up to cycle 24.

II. To examine the impact of differential treatment response (PFS), if observed, on QOL based on the FACT FWB+PWB up to cycle 48.

III. To obtain prospective data on myeloma specific QOL attributes, utilizing and evaluating the Multiple Myeloma Subscale (MMS).

OUTLINE:

PHASE II: Patients receive lenalidomide orally (PO) once daily (QD) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

PHASE III: Patients are randomized to 1 of 2 treatment arms.

ARM A: Patients receive lenalidomide PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

ARM B: Patients undergo observation until progression to symptomatic myeloma.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then every 12 months for 5 years.

Eligibility Criteria

Inclusion Criteria:

Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting cycle 1 of lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy; a FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months); all patients must be counseled by a trained counselor every 28 days about pregnancy precautions and risks of fetal exposure

Patients must have no lytic lesions on skeletal surveys and no hypercalcemia (i.e., >= 11 mg/dL)

Hemoglobin >= 11 g/dL

No prior or concurrent systemic or radiation therapy for the treatment of myeloma

Human immunodeficiency virus (HIV) infection is not excluded; HIV+ patients must meet the following criteria:

Cluster of differentiation (CD)4 cell count >= 350/mm^3

No history of acquired immune deficiency syndrome (AIDS)-related illness

Not currently prescribed zidovudine or stavudine

Patients must not have active, uncontrolled infection

Patients should not have New York Heart Association classification III or IV heart failure

Patients with a history of prior malignancy are eligible provided they were treated with curative intent and have been free of disease for the time period considered appropriate for cure of the specific cancer; for most diseases this time frame is 5 years

Patients should not be felt to have an immediate need for chemotherapy

Prior glucocorticosteroid therapy for the treatment of multiple myeloma is not permitted

Prior systemic glucocorticosteroid use for the treatment of non-malignant disorders is permitted; concurrent use after registration on the study should be restricted to the equivalent of prednisone 10 mg per day

Patients must not have baseline bone lesions or plasmacytomas

Patients with monoclonal gammopathy of undetermined significance are not eligible

Platelet count >= 100,000/mm^3

Bilirubin =< 1.5 mg/dL

Calculated creatinine clearance >= 30 mL/min

Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

Patients must not have grade 2 or higher peripheral neuropathy

Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but are required to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation

Patients must be diagnosed with asymptomatic high-risk smoldering multiple myeloma (SMM) within the past 60 months, as confirmed by both of the following:

Bone marrow plasmacytosis with >= 10% plasma cells or sheets of plasma cells at any time before initiating study treatment, including a marrow which must be obtained by bone marrow aspiration and/or biopsy within 4 weeks prior to randomization

Abnormal serum free light chain ratio (< 0.26 or > 1.65) by serum free light chain (FLC) assay; FLC assay must be performed within 28 days of randomization

Patients must have measurable levels of monoclonal protein (M-protein): >= 1g/dL on serum protein electrophoresis or >= 200 mg of monoclonal protein on a 24 hour urine protein electrophoresis which must be obtained within 4 weeks prior to randomization

Concurrent use of bisphosphonates is not permitted; however, prior bisphosphonates or once-a-year intravenous bisphosphonate given for the treatment of osteoporosis is permitted

Prior or concurrent use of erythropoietin is disallowed

Prior or concurrent topical or localized glucocorticosteroid therapy to treat non-malignant comorbid disorders is permitted

Patients must not have active, uncontrolled seizure disorder; patients must have had no seizures in the last 6 months

Patients must not have uncontrolled intercurrent illness including uncontrolled hypertension, symptomatic congestive heart failure, unstable angina, uncontrolled cardiac arrhythmia, uncontrolled psychiatric illness or social situation that would limit compliance with the study, or a prior history of Stevens Johnson Syndrome

Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) and serum glutamic oxaloacetic transaminase (SGPT) (aspartate aminotransferase [AST]) =< 2.5 times upper limit of normal

Absolute neutrophil count (ANC) >= 1,500/mm^3

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

National Cancer Institute

  • National Cancer Institute
Sagar Lonial, Principal Investigator

Trial Sites

U.S.A.

Alaska
Anchorage

Alaska Breast Care and Surgery LLC

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Alaska Women's Cancer Care

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Anchorage Oncology Centre

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Katmai Oncology Group

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Providence Alaska Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Arizona
Scottsdale

Mayo Clinic in Arizona

John A. Lust
Ph: 507-538-7623

John A. Lust
Principal Investigator

California
Burbank

Providence Saint Joseph Medical Center/Disney Family Cancer Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Modesto

Memorial Medical Center

David Alan Shiba
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

David Alan Shiba
Principal Investigator

Mountain View

Palo Alto Medical Foundation-Camino Division

David Alan Shiba
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

David Alan Shiba
Principal Investigator

Orange

UC Irvine Health/Chao Family Comprehensive Cancer Center

Kanwarpal S. Kahlon
Ph: 877-827-8839
Email: ucstudy@uci.edu

Kanwarpal S. Kahlon
Principal Investigator

Palo Alto

Palo Alto Medical Foundation Health Care

Peter Paul Yu
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Peter Paul Yu
Principal Investigator

San Francisco

UCSF Medical Center-Parnassus

Anuj Kumar Mahindra
Ph: 877-827-3222

Anuj Kumar Mahindra
Principal Investigator

Santa Rosa

Sutter Pacific Medical Foundation

David Alan Shiba
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

David Alan Shiba
Principal Investigator

Sunnyvale

Palo Atlo Medical Foundation-Sunnyvale

Peter Paul Yu
Ph: 415-209-2686
Email: bernicl@sutterhealth.org

Peter Paul Yu
Principal Investigator

Colorado
Aurora

Rocky Mountain Cancer Centers-Aurora

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

The Medical Center of Aurora

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Boulder

Boulder Community Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Colorado Springs

Penrose-Saint Francis Healthcare

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Penrose

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Denver

Colorado Blood Cancer Institute

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Colorado Cancer Research Program CCOP

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Exempla Saint Joseph Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Presbyterian - Saint Lukes Medical Center - Health One

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Midtown

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Rose

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rose Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Durango

Mercy Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Englewood

Comprehensive Cancer Care and Research Institute of Colorado LLC

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Swedish Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Golden

Mountain Blue Cancer Care Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Greeley

North Colorado Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Greenwood Village

Rocky Mountain Cancer Centers-Greenwood Village

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Lakewood

Rocky Mountain Cancer Centers-Lakewood

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Saint Anthony Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Littleton

Littleton Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Littleton

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Lone Tree

Rocky Mountain Cancer Centers-Sky Ridge

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Sky Ridge Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Longmont

Longmont United Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Loveland

McKee Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Parker

Parker Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Rocky Mountain Cancer Centers-Parker

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Pueblo

Saint Mary Corwin Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Thornton

Rocky Mountain Cancer Centers-Thornton

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Wheat Ridge

Exempla Lutheran Medical Center

Keren Sturtz
Ph: 888-785-6789

Keren Sturtz
Principal Investigator

Connecticut
Danbury

Danbury Hospital

Vincent A. Rella
Ph: 203-739-8074

Vincent A. Rella
Principal Investigator

Hartford

Saint Francis Hospital and Medical Center

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

New Haven

Yale University

Madhav V. Dhodapkar
Ph: 203-785-5702

Madhav V. Dhodapkar
Principal Investigator

Norwich

Eastern Connecticut Hematology and Oncology Associates

Dennis E. Slater
Ph: 860-886-8362

Dennis E. Slater
Principal Investigator

Delaware
Lewes

Beebe Medical Center

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Newark

Christiana Care Health System-Christiana Hospital

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Delaware Clinical and Laboratory Physicians PA

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Helen F Graham Cancer Center

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Medical Oncology Hematology Consultants PA

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Regional Hematology and Oncology PA

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Rehoboth Beach

Beebe Health Campus

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Seaford

Nanticoke Memorial Hospital

Gregory Andrew Masters
Ph: 302-733-6227

Gregory Andrew Masters
Principal Investigator

Florida
Hollywood

Memorial Regional Hospital/Joe DiMaggio Children's Hospital

Neil Nagovski
Ph: 888-823-5923
Email: ctsucontact@westat.com

Neil Nagovski
Principal Investigator

Miami Beach

Mount Sinai Medical Center

Michael A. Schwartz
Ph: 305-674-2625
Email: info@msccop.com

Michael A. Schwartz
Principal Investigator

Orlando

Florida Hospital Orlando

Lee M. Zehngebot
Ph: 407-303-5623

Lee M. Zehngebot
Principal Investigator

Georgia
Albany

Phoebe Putney Memorial Hospital

Jose M. Tongol
Ph: 229-312-2251

Jose M. Tongol
Principal Investigator

Atlanta

Emory University/Winship Cancer Institute

Sagar Lonial
Ph: 404-778-1868

Sagar Lonial
Principal Investigator

Northside Hospital

Thomas Edwin Seay
Ph: 404-303-3355

Thomas Edwin Seay
Principal Investigator

Augusta

Georgia Regents University Medical Center

Sharad Anant Ghamande
Ph: 706-721-1663
Email: cancer@georgiahealth.edu

Sharad Anant Ghamande
Principal Investigator

Decatur

Dekalb Medical Center

Jayanthi Srinivasiah
Ph: 404-501-3279

Jayanthi Srinivasiah
Principal Investigator

Macon

Medical Center of Central Georgia

Frederick M. Schnell
Ph: 404-501-3279

Frederick M. Schnell
Principal Investigator

Savannah

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

Mark Alexander Taylor
Ph: 912-350-8568

Mark Alexander Taylor
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Post Falls

Kootenai Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Illinois
Bloomington

Illinois CancerCare-Bloomington

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Canton

Illinois CancerCare-Canton

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Carthage

Illinois CancerCare-Carthage

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Chicago

Advocate Illinois Masonic Medical Center

Denise Angelique Levitan
Ph: 773-296-5360

Denise Angelique Levitan
Principal Investigator

University of Illinois

Pritesh Patel
Ph: 312-355-3046

Pritesh Patel
Principal Investigator

Danville

Carle on Vermilion

James R. Egner
Ph: 800-446-5532

James R. Egner
Principal Investigator

Decatur

Cancer Care Center of Decatur

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Decatur Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Effingham

Carle Physician Group-Effingham

James R. Egner
Ph: 800-446-5532

James R. Egner
Principal Investigator

Eureka

Illinois CancerCare-Eureka

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Galesburg

Illinois CancerCare-Galesburg Cottage Plaza Office

Nguyet Anh Le-Lindqwister
Ph: 800-793-2262

Nguyet Anh Le-Lindqwister
Principal Investigator

Kewanee

Illinois CancerCare-Kewanee Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Macomb

Illinois CancerCare-Macomb

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Mattoon

Carle Physician Group-Mattoon/Charleston

James R. Egner
Ph: 800-446-5532

James R. Egner
Principal Investigator

Maywood

Loyola University Medical Center

Kevin Patrick Barton
Ph: 708-226-4357

Kevin Patrick Barton
Principal Investigator

Ottawa

Illinois CancerCare-Ottawa Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Pekin

Illinois CancerCare-Pekin

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peoria

Illinois CancerCare-Peoria

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peru

Illinois CancerCare-Peru

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Princeton

Illinois CancerCare-Princeton

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Rockford

SwedishAmerican Regional Cancer Center/ACT

Harvey E. Einhorn
Ph: 779-696-9400
Email: cancercare@swedishamerican.org

Harvey E. Einhorn
Principal Investigator

Springfield

Central Illinois Hematology Oncology Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Memorial Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southern Illinois University School of Medicine

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Springfield Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Urbana

Carle Cancer Center

James R. Egner
Ph: 800-446-5532

James R. Egner
Principal Investigator

The Carle Foundation Hospital

James R. Egner
Ph: 800-446-5532

James R. Egner
Principal Investigator

Indiana
Lafayette

IU Health Arnett Cancer Care

Bamidele Andrew Adesunloye
Ph: 317-356-2422
Email: thimes@iuhealth.org

Bamidele Andrew Adesunloye
Principal Investigator

Richmond

Reid Hospital and Health Care Services

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

South Bend

Memorial Hospital of South Bend

Thomas Joseph Reid
Ph: 800-284-7370

Thomas Joseph Reid
Principal Investigator

Iowa
Ames

McFarland Clinic PC-William R Bliss Cancer Center

Joseph James Merchant
Ph: 515-239-2621

Joseph James Merchant
Principal Investigator

Cedar Rapids

Oncology Associates at Mercy Medical Center

Deborah Weil Wilbur
Ph: 319-363-2690

Deborah Weil Wilbur
Principal Investigator

Clive

Medical Oncology and Hematology Associates-West Des Moines

Richard L. Deming
Ph: 888-221-4849

Richard L. Deming
Principal Investigator

Mercy Cancer Center-West Lakes

Richard L. Deming
Ph: 888-221-4849

Richard L. Deming
Principal Investigator

Des Moines

Medical Oncology and Hematology Associates-Laurel

Richard L. Deming
Ph: 888-221-4849

Richard L. Deming
Principal Investigator

Mercy Medical Center - Des Moines

Richard L. Deming
Ph: 888-221-4849

Richard L. Deming
Principal Investigator

Mason City

Mercy Medical Center - North Iowa

Arvind Y. Vemula
Ph: 800-433-3883

Arvind Y. Vemula
Principal Investigator

Sioux City

Siouxland Regional Cancer Center

Donald B. Wender
Ph: 712-252-0088

Donald B. Wender
Principal Investigator

West Des Moines

Mercy Medical Center-West Lakes

Richard L. Deming
Ph: 888-221-4849

Richard L. Deming
Principal Investigator

Kansas
Great Bend

Saint Rose Ambulatory and Surgery Center

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Kansas City

Kansas City Cancer Center-West

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

University of Kansas Cancer Center

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Lawrence

Lawrence Memorial Hospital

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Salina

Salina Regional Health Center

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Topeka

Stormont-Vail Regional Health Center

David E. Einspahr
Ph: 785-270-4963

David E. Einspahr
Principal Investigator

Wichita

Wesley Medical Center

Shaker R. Dakhil
Ph: 316-262-4467

Shaker R. Dakhil
Principal Investigator

Kentucky
Louisville

Jewish Hospital

Richard L. Deming
Ph: 888-221-4849

Richard L. Deming
Principal Investigator

Jewish Hospital Medical Center Northeast

Richard L. Deming
Ph: 888-221-4849

Richard L. Deming
Principal Investigator

Louisiana
Baton Rouge

Ochsner Health Center-Summa

Furhan Yunus
Ph: 504-842-3708

Furhan Yunus
Principal Investigator

New Orleans

Ochsner Medical Center Jefferson

Furhan Yunus
Ph: 504-842-3708

Furhan Yunus
Principal Investigator

Tulane University Health Sciences Center

Hana F. Safah
Ph: 504-988-6121

Hana F. Safah
Principal Investigator

Maryland
Bethesda

Walter Reed National Military Medical Center

Mary Lee Kwok
Ph: 301-319-2100

Mary Lee Kwok
Principal Investigator

Massachusetts
Boston

Tufts Medical Center

Raymond Luke Comenzo
Ph: 617-636-5000
Email: ContactUsCancerCenter@TuftsMedicalCenter.org

Raymond Luke Comenzo
Principal Investigator

Worcester

University of Massachusetts Medical School

Doreen Barbara Brettler
Ph: 508-856-3216
Email: cancer.research@umassmed.edu

Doreen Barbara Brettler
Principal Investigator

Michigan
Ann Arbor

Saint Joseph Mercy Hospital

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Dearborn

Oakwood Hospital and Medical Center

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Detroit

Saint John Hospital and Medical Center

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Wayne State University/Karmanos Cancer Institute

Divaya Bhutani
Ph: 313-576-9363

Divaya Bhutani
Principal Investigator

Flint

Genesys Hurley Cancer Institute

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Jackson

Allegiance Health

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Kalamazoo

West Michigan Cancer Center

Sunil Nagpal
Ph: 269-373-7458

Sunil Nagpal
Principal Investigator

Livonia

Saint Mary Mercy Hospital

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Pontiac

Saint Joseph Mercy Oakland

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Port Huron

Saint Joseph Mercy Port Huron

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Saginaw

Saint Mary's of Michigan

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Southfield

Providence Hospital

Howard R. Terebelo
Ph: 248-849-5337
Email: jaswinder.grewal@stjohn.org

Howard R. Terebelo
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

Christopher M. Reynolds
Ph: 734-712-4673

Christopher M. Reynolds
Principal Investigator

Minnesota
Burnsville

Fairview Ridges Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Coon Rapids

Mercy Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Duluth

Essentia Health Cancer Center

Bret E.B. Friday
Ph: 888-203-7267

Bret E.B. Friday
Principal Investigator

Edina

Fairview-Southdale Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Fergus Falls

Lake Region Healthcare Corporation-Cancer Care

Bret E.B. Friday
Ph: 888-203-7267

Bret E.B. Friday
Principal Investigator

Fridley

Unity Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Hutchinson

Hutchinson Area Health Care

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Maplewood

Minnesota Oncology Hematology PA-Maplewood

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Saint John's Hospital - Healtheast

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Minneapolis

Abbott-Northwestern Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Health Partners Inc

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Hennepin County Medical Center

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Robbinsdale

North Memorial Medical Health Center

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Rochester

Mayo Clinic

John A. Lust
Ph: 507-538-7623

John A. Lust
Principal Investigator

Saint Louis Park

Park Nicollet Clinic - Saint Louis Park

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Saint Paul

Regions Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

United Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Shakopee

Saint Francis Regional Medical Center

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Waconia

Ridgeview Medical Center

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Willmar

Rice Memorial Hospital

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Woodbury

Minnesota Oncology and Hematology PA-Woodbury

Joseph W. Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Joseph W. Leach
Principal Investigator

Missouri
Bolivar

Central Care Cancer Center-Carrie J Babb Cancer Center

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Cape Girardeau

Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southeast Cancer Center

Bryan A. Faller
Ph: 800-392-0936

Bryan A. Faller
Principal Investigator

Jefferson City

Capital Region Medical Center-Goldschmidt Cancer Center

Bryan A. Faller
Ph: 800-392-0936

Bryan A. Faller
Principal Investigator

Kansas City

Kansas City Cancer Center - South

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Kansas City Cancer Centers - North

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Kansas City Veterans Affairs Medical Center

Suman Kambhampati
Ph: 800-525-1483

Suman Kambhampati
Principal Investigator

Truman Medical Center

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Lee's Summit

Kansas City Cancer Center-Lee's Summit

Peter J. Van Veldhuizen
Ph: 800-525-1483

Peter J. Van Veldhuizen
Principal Investigator

Saint Louis

Mercy Hospital Saint Louis

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Missouri Baptist Medical Center

Bryan A. Faller
Ph: 800-392-0936

Bryan A. Faller
Principal Investigator

Saint Louis Cancer and Breast Institute-South City

Jay W. Carlson
Ph: 800-821-7532

Jay W. Carlson
Principal Investigator

Montana
Billings

Billings Clinic Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Bozeman

Bozeman Deaconess Hospital

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Butte

Saint James Community Hospital and Cancer Treatment Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Great Falls

Benefis Healthcare- Sletten Cancer Institute

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Nebraska
Grand Island

CHI Health Saint Francis

Richard L. Deming
Ph: 888-221-4849

Richard L. Deming
Principal Investigator

Kearney

CHI Health Good Samaritan

Richard L. Deming
Ph: 888-221-4849

Richard L. Deming
Principal Investigator

Lincoln

Nebraska Cancer Research Center

Gamini S. Soori
Ph: 402-991-8070
Email: mwilwerding@mvcc.cc

Gamini S. Soori
Principal Investigator

Nevada
Las Vegas

Cancer and Blood Specialists-Fort Apache

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

Nevada Cancer Research Foundation CCOP

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

University Medical Center of Southern Nevada

John Allan Ellerton
Ph: 702-384-0013

John Allan Ellerton
Principal Investigator

New Jersey
Camden

Cooper Hospital University Medical Center

Neil A. Lachant
Ph: 856-325-6757

Neil A. Lachant
Principal Investigator

East Orange

Veterans Adminstration New Jersey Health Care System

Victor Tsu-Shih Chang
Ph: 800-475-2336
Email: patricia.goyer@med.va.gov

Victor Tsu-Shih Chang
Principal Investigator

Newark

Newark Beth Israel Medical Center

Lori Schleicher
Ph: 973-926-7230

Lori Schleicher
Principal Investigator

Vineland

Inspira Medical Center Vineland

Ramakrishna R. Sudhindra
Ph: 856-641-7933

Ramakrishna R. Sudhindra
Principal Investigator

Woodbury

Inspira Medical Center Woodbury

Ramakrishna R. Sudhindra
Ph: 856-641-7933

Ramakrishna R. Sudhindra
Principal Investigator

New Mexico
Albuquerque

Presbyterian Kaseman Hospital

Dulcinea Dolores Quintana
Ph: 505-272-6972

Dulcinea Dolores Quintana
Principal Investigator

University of New Mexico

Dulcinea Dolores Quintana
Ph: 505-272-6972

Dulcinea Dolores Quintana
Principal Investigator

New York
Bronx

Albert Einstein College of Medicine

Ramakrishna Battini
Ph: 718-904-2730
Email: aecc@aecom.yu.edu

Ramakrishna Battini
Principal Investigator

Montefiore Medical Center - Moses Campus

Ramakrishna Battini
Ph: 718-904-2730
Email: aecc@aecom.yu.edu

Ramakrishna Battini
Principal Investigator

North Carolina
Clinton

Southeastern Medical Oncology Center-Clinton

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Goldsboro

Southeastern Medical Oncology Center-Goldsboro

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Wayne Memorial Hospital

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Jacksonville

Southeastern Medical Oncology Center-Jacksonville

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Kinston

Kinston Medical Specialists PA

Peter Robins Watson
Ph: 252-559-2200

Peter Robins Watson
Principal Investigator

Statesville

Iredell Memorial Hospital

Ruby Ann Grimm
Ph: 704-873-5661

Ruby Ann Grimm
Principal Investigator

Wilson

Southeastern Medical Oncology Center-Wilson

James N. Atkins
Ph: 919-580-0000

James N. Atkins
Principal Investigator

Winston-Salem

Wake Forest University Health Sciences

Rakhee Vaidya
Ph: 336-713-6771

Rakhee Vaidya
Principal Investigator

Ohio
Canton

Mercy Medical Center

Mitchell Haut
Ph: 888-293-4673

Mitchell Haut
Principal Investigator

Chardon

Geaugra Hospital

Hillard Michael Lazarus
Ph: 800-641-2422

Hillard Michael Lazarus
Principal Investigator

Cincinnati

Good Samaritan Hospital - Cincinnati

Richard L. Deming
Ph: 888-221-4849

Richard L. Deming
Principal Investigator

TriHealth Cancer Institute-Anderson

Richard L. Deming
Ph: 888-221-4849

Richard L. Deming
Principal Investigator

TriHealth Cancer Institute-Westside

Richard L. Deming
Ph: 888-221-4849

Richard L. Deming
Principal Investigator

Cleveland

Case Western Reserve University

Hillard Michael Lazarus
Ph: 800-641-2422

Hillard Michael Lazarus
Principal Investigator

MetroHealth Medical Center

Bruce J. Averbook
Ph: 216-778-8526
Email: kbauchens@metrohealth.org

Bruce J. Averbook
Principal Investigator

Columbus

Columbus Oncology and Hematology Associates Inc

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Mount Carmel Health Center West

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Riverside Methodist Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

The Mark H Zangmeister Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Dayton

Good Samaritan Hospital - Dayton

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Miami Valley Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Samaritan North Health Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Findlay

Blanchard Valley Hospital

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Lima

Saint Rita's Medical Center

Henry Gerad
Ph: 419-226-9617

Henry Gerad
Principal Investigator

Marietta

Marietta Memorial Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Mayfield Heights

Ireland Cancer Center Landerbrook Health Center

Hillard Michael Lazarus
Ph: 800-641-2422

Hillard Michael Lazarus
Principal Investigator

Mentor

Lake University Ireland Cancer Center

Hillard Michael Lazarus
Ph: 800-641-2422

Hillard Michael Lazarus
Principal Investigator

Newark

Licking Memorial Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Sandusky

Ireland Cancer Center at Firelands Regional Medical Center

Hillard Michael Lazarus
Ph: 800-641-2422

Hillard Michael Lazarus
Principal Investigator

Springfield

Springfield Regional Cancer Center

Howard M. Gross
Ph: 937-775-1350

Howard M. Gross
Principal Investigator

Springfield Regional Medical Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Westerville

Saint Ann's Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Westlake

UHHS-Westlake Medical Center

Hillard Michael Lazarus
Ph: 800-641-2422

Hillard Michael Lazarus
Principal Investigator

UH-Seidman Cancer Center at Saint John Medical Center

Hillard Michael Lazarus
Ph: 800-641-2422

Hillard Michael Lazarus
Principal Investigator

Oregon
Newberg

Providence Newberg Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Oregon City

Providence Willamette Falls Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Portland

Providence Portland Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Providence Saint Vincent Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Pennsylvania
Danville

Geisinger Medical Center

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Hazleton

Geisinger Medical Center-Cancer Center Hazleton

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Hershey

Penn State Milton S Hershey Medical Center

Giampaolo Talamo
Ph: 717-531-3779
Email: CTO@hmc.psu.edu

Giampaolo Talamo
Principal Investigator

Pittsburgh

West Penn Hospital

Entezam Asim Sahovic
Ph: 412-578-1034

Entezam Asim Sahovic
Principal Investigator

Pottstown

Pottstown Memorial Medical Center

Wei (Frank) Song
Ph: 610-327-7544

Wei (Frank) Song
Principal Investigator

Sayre

Guthrie Medical Group PC-Robert Packer Hospital

Bradley Walter Lash
Ph: 800-836-0388

Bradley Walter Lash
Principal Investigator

Wilkes-Barre

Geisinger Wyoming Valley/Henry Cancer Center

Edward J. Gorak
Ph: 570-271-5251

Edward J. Gorak
Principal Investigator

Williamsport

Susquehanna Cancer Center

Warren Lewis Robinson
Ph: 800-598-4282

Warren Lewis Robinson
Principal Investigator

PR
San Juan

Fundacion De Investigacion de Diego

Deana Hallman Navarro
Ph: 787-765-2363

Deana Hallman Navarro
Principal Investigator

South Carolina
Charleston

Charleston Hematology Oncology Associates PA-St. Francis

James Michael Orcutt
Ph: 843-720-8386
Email: elizabeth.strojny@roperstfrancis.com

James Michael Orcutt
Principal Investigator

Charleston Hematology Oncology Associates-Roper

James Michael Orcutt
Ph: 843-720-8386
Email: elizabeth.strojny@roperstfrancis.com

James Michael Orcutt
Principal Investigator

Roper Hospital

James Michael Orcutt
Ph: 843-720-8386
Email: elizabeth.strojny@roperstfrancis.com

James Michael Orcutt
Principal Investigator

Easley

Greenville Health System Cancer Institute-Easley

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville

Greenville Health System Cancer Institute-Butternut

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville Health System Cancer Institute-Eastside

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville Health System Cancer Institute-Faris

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville Memorial Hospital

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Saint Francis Hospital

Robert D. Siegel
Ph: 864-255-1713

Robert D. Siegel
Principal Investigator

Greer

Greenville Health System Cancer Institute-Greer

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Mount Pleasant

Lowcountry Hematology Oncology PA-Mount Pleasant

James Michael Orcutt
Ph: 843-720-8386
Email: elizabeth.strojny@roperstfrancis.com

James Michael Orcutt
Principal Investigator

Seneca

Greenville Health System Cancer Institute-Seneca

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Spartanburg

Greenville Health System Cancer Institute-Spartanburg

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

South Dakota
Rapid City

Rapid City Regional Hospital

Joshua Cole Lukenbill
Ph: 605-716-3982
Email: research@rcrh.org

Joshua Cole Lukenbill
Principal Investigator

Tennessee
Jackson

Jackson-Madison County General Hospital

Dwight C. Kaufman
Ph: 731-425-6865

Dwight C. Kaufman
Principal Investigator

Texas
Dallas

UT Southwestern/Simmons Cancer Center-Dallas

Larry D. Anderson
Ph: 214-648-7097

Larry D. Anderson
Principal Investigator

Lubbock

Covenant Medical Center-Lakeside

Donald Paul Quick
Ph: 806-725-8000
Email: jaccresearch@covhs.org

Donald Paul Quick
Principal Investigator

Vermont
Rutland

Rutland Regional Medical Center

Allan Daniel Eisemann
Ph: 802-775-7111

Allan Daniel Eisemann
Principal Investigator

Virginia
Danville

Danville Regional Medical Center

Qiwei William Gai
Ph: 434-793-0044

Qiwei William Gai
Principal Investigator

Washington
Longview

Saint John Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Puyallup

MultiCare Good Samaritan Hospital

John A. Keech
Ph: 907-458-5380

John A. Keech
Principal Investigator

Tacoma

Multicare Health System

John A. Keech
Ph: 907-458-5380

John A. Keech
Principal Investigator

Vancouver

PeaceHealth Southwest Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

West Virginia
Charleston

West Virginia University Charleston

Steven James Jubelirer
Ph: 304-344-3457

Steven James Jubelirer
Principal Investigator

Wisconsin
Burlington

Aurora Cancer Care-Burlington

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Chippewa Falls

Marshfield Clinic-Chippewa Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Eau Claire

Marshfield Clinic Cancer Center at Sacred Heart

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Elkhorn

Aurora Cancer Care-Southern Lakes

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Grafton

Aurora Cancer Care-Grafton

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Green Bay

Aurora BayCare Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Kenosha

Aurora Cancer Care-Kenosha South

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

La Crosse

Gundersen Lutheran Medical Center

Kurt Oettel
Ph: 608-775-2385
Email: cancerctr@gundluth.org

Kurt Oettel
Principal Investigator

Marinette

Vince Lombardi Cancer Clinic-Marinette

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Marshfield

Marshfield Clinic

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Menomonee Falls

Aurora Advanced Healthcare Inc-Menomonee Falls

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Mequon

Columbia Saint Mary's Hospital - Ozaukee

Charles H. I. Tiber
Ph: 414-326-2675
Email: clinicaltrials@columbia-stmarys.org

Charles H. I. Tiber
Principal Investigator

Milwaukee

Aurora Cancer Care-Milwaukee

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Aurora Cancer Care-Milwaukee South

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Aurora Saint Luke's Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Aurora Sinai Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Columbia Saint Mary's Water Tower Medical Commons

Charles H. I. Tiber
Ph: 414-326-2675
Email: clinicaltrials@columbia-stmarys.org

Charles H. I. Tiber
Principal Investigator

Minocqua

Marshfield Clinic-Minocqua Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Oconomowoc

Oconomowoc Memorial Hospital-ProHealth Care Inc

Timothy Robert Wassenaar
Ph: 262-928-7878

Timothy Robert Wassenaar
Principal Investigator

Oshkosh

Vince Lombardi Cancer Clinic - Oshkosh

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Racine

Aurora Cancer Care-Racine

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Rhinelander

Marshfield Clinic at James Beck Cancer Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Rice Lake

Marshfield Clinic-Rice Lake Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Sheboygan

Vince Lombardi Cancer Clinic-Sheboygan

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Stevens Point

Marshfield Clinic Cancer Care at Saint Michael's Hospital

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Summit

Aurora Medical Center in Summit

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Two Rivers

Vince Lombardi Cancer Clinic

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Waukesha

Aurora Cancer Care-Waukesha

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Waukesha Memorial Hospital

Timothy Robert Wassenaar
Ph: 262-928-7878

Timothy Robert Wassenaar
Principal Investigator

Wauwatosa

Aurora Cancer Care-Milwaukee West

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

West Allis

Aurora West Allis Medical Center

Dhimant R. Patel
Ph: 800-252-2990

Dhimant R. Patel
Principal Investigator

Weston

Diagnostic and Treatment Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Marshfield Clinic - Weston Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Wisconsin Rapids

Marshfield Clinic - Wisconsin Rapids Center

Douglas J. Reding
Ph: 715-389-4457

Douglas J. Reding
Principal Investigator

Ireland

Dublin

Mater Misericordiae University Hospital

Michael E O'Dwyer
Ph: 353 1 8287100
Email: info@cancercontrol.ie

Michael E O'Dwyer
Principal Investigator

Mater Private Hospital

Michael E O'Dwyer
Ph: 353 1 8287100
Email: info@cancercontrol.ie

Michael E O'Dwyer
Principal Investigator

Galway

University College Hospital Galway

Michael E O'Dwyer
Ph: 353 1 8287100
Email: info@cancercontrol.ie

Michael E O'Dwyer
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01169337

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.